Hemostatic efficacy and safety of preemptive antifibrinolysis with multi-dose intravenous tranexamic acid in acute traumatic bleeding patients.

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100051194

Enrollment

Unknown

Registered

2021-09-15

Start date

2021-09-01

Completion date

Unknown

Last updated

2022-05-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute traumatic bleeding diseases

Interventions

Group A:100 ml N.S. i.v. q12h

Group B:1.5 g TXA i.v. q12h

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1.Aged over 18 years; 2.Admitted to our medical center for acute bleeding diseases and require surgical treatment.

Exclusion criteria

Exclusion criteria: 1. Complicated with severe cardiovascular and cerebrovascular diseases (myocardial infarction, cerebral infarction, etc.); 2. Obvious bleeding tendency (such as active gastrointestinal bleeding, cerebral hemorrhage, etc.); 3. Combined with systemic or local venous thromboembolism (such as deep vein thrombosis, pulmonary embolism, etc.); 4. Previously definite coagulation dysfunction; 5. Combined with severe neuromuscular disease; 6. Allergy to tranexamic acid.

Design outcomes

Primary

Measure	Time frame
Hidden blood loss;Decline of hemoglobin level;Blood transfusion rate;	—

Secondary

Measure	Time frame
D-dimer;fibrinogen degradation products;Thrombelastography;prothrombin time;activated partial thromboplastin time;ESR;C reactive protein;procalcitonin;IL-6;Deep vein thrombosis of lower extremity;Anti Xa-Factor activity;	—

Countries

China

Contacts

Public ContactHuang Wei

The First Affiliated Hospital of Chongqing Medical University

huangwei68@263.net+86 13883383330

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026